Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on serious diseases like NASH and obesity, will present at the 21st Annual Needham Virtual Healthcare Conference.

The presentation is scheduled for April 11, 2022, at 2:15 p.m. ET. Investors can access a live audio webcast via Terns' investor relations webpage, with a replay available for 30 days post-event.

Terns is developing a diverse pipeline of therapies, including an FXR agonist and a VAP-1 inhibitor.

FOSTER CITY, Calif., March 21, 2022 – Terns Pharmaceuticals (Nasdaq: TERN) announced top-line results from Part 1 of the Phase 1b AVIATION Trial for TERN-201, a VAP-1 inhibitor aimed at treating non-alcoholic steatohepatitis (NASH). Part 1 met the primary safety endpoint, showing TERN-201 was well-tolerated with mild to moderate adverse events, but did not demonstrate significant changes in NASH biomarkers compared to placebo. Part 2 of the trial with a higher dose is ongoing, with results expected in H2 2022. Terns maintains a cash runway into 2024 and plans further trials for other candidates.

Terns Pharmaceuticals, Inc. reported significant developments in its clinical pipeline and financial results for 2021. Expected top-line data from TERN-201's NASH trial will be released in March 2022, while TERN-501 will begin its first NASH trial in H1 2022, with results anticipated in H2 2023. The company holds $166 million in cash, providing funding into 2024. R&D expenses rose to $31.3 million, contributing to a net loss of $50.2 million for the year. Despite these losses, Terns' leadership changes and pipeline advancements position it for future growth, focusing on serious diseases like NASH and obesity.

Terns Pharmaceuticals (Nasdaq: TERN) announced its participation in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 12:50 PM ET. The event will address serious diseases, including NASH and obesity, which are central to Terns' clinical focus. A live webcast will be accessible on Terns' investor relations page, with a replay available for 30 days post-presentation. The company is advancing a pipeline featuring small-molecule therapies and combination treatments aimed at improving patient outcomes.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced the appointment of Jeffrey R. Jasper, Ph.D., as Senior Vice President and Head of Research, and the promotion of Diana Chung to Senior Vice President and Chief Development Officer. Dr. Jasper brings over 28 years of industry experience, having held key roles at Rubedo Life Sciences and Merck. Chung has over 20 years of experience in drug discovery and clinical development. Terns aims to advance its pipeline towards a combination trial for NASH in 2022, leveraging the expertise of its strengthened leadership team.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on serious diseases like non-alcoholic steatohepatitis (NASH), will showcase its progress at upcoming investor conferences. The key events are the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, at 11:15 a.m. ET, and the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. Interested parties can access live audio webcasts and replays on Terns' investor relations website.

Terns Pharmaceuticals reported strong progress in its clinical pipeline and financial health for Q3 2021, with cash reserves of $177 million projected to sustain operations into 2024. The company announced positive top-line data from TERN-501 supporting its role as a promising THR-β agonist in treating non-alcoholic steatohepatitis (NASH), and is set to initiate new trials in 1H 2022. The third quarter net loss was $11.8 million, slightly higher than the previous year, but R&D expenses rose to $7.2 million aimed at advancing its clinical candidates.

Terns Pharmaceuticals announced positive results from the Phase 2a LIFT Trial of TERN-101, demonstrating significant decreases in cT1, a marker of liver inflammation and fibrosis, over 12 weeks of treatment. The trial showed TERN-101 to be safe and well-tolerated, correlating cT1 improvements with reduced clinical event risks. Additionally, Phase 1 data for TERN-501 indicated well-tolerated single doses leading to significant LDL decreases and SHBG increases, pointing to its potential efficacy in treating NASH. Both compounds are pivotal in Terns' NASH treatment strategy.

Terns Pharmaceuticals reported positive Phase 1 clinical trial results for TERN-501, a THR-β agonist targeting non-alcoholic steatohepatitis (NASH). The trial showed that TERN-501 was generally safe, well-tolerated, and demonstrated favorable pharmacokinetic properties with a half-life of over 13 hours. Significant reductions in LDL cholesterol of up to 28% and marked increases in sex hormone binding globulin were observed. Terns plans to initiate an FXR/THR-β agonist combination trial in NASH in the first half of 2022.